Is Mereo BioPharma Group plc financially healthy?

Mereo BioPharma Group plc scores 3 out of 7 on the Piotroski F-score. Only 7 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Its Altman Z-score puts it in the distress zone. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.

Who are the largest institutional holders of Mereo BioPharma Group plc?

Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are BANK OF AMERICA CORP /DE/ (trimming), CITADEL ADVISORS LLC (adding), STATE STREET CORP (adding). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.

Mereo BioPharma Group plc (MREO)

Nasdaq · ADR · Pharmaceutical Preparations

One email a week from me: what it filed, which 13F holders added or cut, where its scores stand. Free.

company in London, United Kingdom

Financial health

Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.

Piotroski F-score

3 / 7

FAILReturn on assets positiveROA -91.2%
FAILOperating cash flow positiveOCF -31M
FAILReturn on assets improving-56.6% → -91.2%
PASSCash flow exceeds earningsOCF -31M vs NI -42M
FAILLong-term debt ratio fallingno debt reported
PASSCurrent ratio improving5.40 → 10.46
FAILNo share dilution740M → 797M shares
FAILGross margin improvingno gross profit reported
PASSAsset turnover improving0.00× → 0.01×

Altman Z-score

-10.38distress

Bankruptcy-risk screen combining working capital, retained earnings, operating income, market value against liabilities, and asset turnover. Above 2.99 is the safe zone; below 1.81 is distress.

Cash conversion: 74.0%
Share count change: 7.8%

Six-year record

Year	Revenue	Net income	Free cash flow	Gross margin	Shares
FY2022	$0	−$42.2M	−$48.8M	—	603,196,403
FY2023	$10.0M	−$29.5M	−$21.1M	—	659,453,921
FY2024	$0	−$43.3M	−$32.8M	—	739,624,264
FY2025	$500,000	−$41.9M	−$31.0M	—	797,119,632

Ownership flow

7 institutions tracked — 5 added, 1 reduced. Active managers added 585,941 shares while index money cut 231,920.

Institutional holders of Mereo BioPharma Group plc and their share-count change
Manager	Kind	Shares	Change	Value
CITADEL ADVISORS LLC	Hedge fund	1,000,058	+545,258	$317.7M
BlackRock, Inc.	Index	69,678	−233,313	$22.1M
JPMORGAN CHASE & CO	Active fund	58,531	+36,683	$19.4M
RENAISSANCE TECHNOLOGIES LLC	Hedge fund	52,100

Identity

CIK: 0001719714
LEI: 213800U8JQHIJOS5AS09
FIGI: BBG00KFWZC67
SIC: 2834 · Pharmaceutical Preparations
Incorporated: United Kingdom
Headquarters: LONDON

Ownership

Institutional: 35.5%
Institutions: 64
Insiders: 0.7%

Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.

Questions about Mereo BioPharma Group plc

Is Mereo BioPharma Group plc financially healthy?: Mereo BioPharma Group plc scores 3 out of 7 on the Piotroski F-score. Only 7 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Its Altman Z-score puts it in the distress zone. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.
Who are the largest institutional holders of Mereo BioPharma Group plc?: Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are BANK OF AMERICA CORP /DE/ (trimming), CITADEL ADVISORS LLC (adding), STATE STREET CORP (adding). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.

This page is one panel of the terminal

The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.

Download the terminal See pricing

Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.